IDEAYA appoints Catherine Mackey, Ph.D. to Board of Directors

IDEAYA Biosciences, Inc.

Dr. Mackey appointed effective April 5, 2022; Board size increased from 8 to 9.
Former SVP of Pfizer Worldwide R&D and Director of Pfizer La Jolla Laboratories; led development of Sutent, Xalkori, Ibrance.
Received option to purchase 22,000 shares at closing price on appointment date, vesting monthly over 36 months.
Current board seats include AVID Bioservices, Rady Children's Hospital; prior boards include Trillium, Poseida, GW Pharma.
CEO highlights her expertise for advancing synthetic lethality pipeline including IDE397 and darovasertib.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Catherine J. Mackey

member of the Board of Directors

IDYA · IDEAYA Biosciences, Inc.

Effective: 2022-04-05
Filed: April 6, 2022, 7:59 PM ET

On April 6, 2022, IDEAYA Biosciences, Inc. (the “Company”) announced the appointment of Catherine J. Mackey, Ph.D. as a member of its Board of Directors (the “Board”), effective April 5, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Catherine J. Mackey was appointed as member of the Board of Directors at IDEAYA Biosciences, Inc..

Action: appointed
Role: member of the Board of Directors

Exact text from the filing

On April 6, 2022, IDEAYA Biosciences, Inc. (the “Company”) announced the appointment of Catherine J. Mackey, Ph.D. as a member of its Board of Directors (the “Board”), effective April 5, 2022.

View on SEC.gov

IDEAYA Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-005384

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.